相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO
Pierre-Yves Dumas et al.
LEUKEMIA (2023)
Sitravatinib as a potent FLT3 inhibitor can overcome gilteritinib resistance in acute myeloid leukemia
Yvyin Zhang et al.
BIOMARKER RESEARCH (2023)
Favorable pharmacokinetic and pharmacodynamic properties of gilteritinib in cerebrospinal fluid: a potential effective treatment in relapsing meningeal acute myeloid leukemia FLT3-ITD patients
Nicolas Vignal et al.
HAEMATOLOGICA (2023)
Overcoming relapse: prophylactic or pre-emptive use of azacitidine or FLT3 inhibitors after allogeneic transplantation for AML or MDS
Yuho Najima
INTERNATIONAL JOURNAL OF HEMATOLOGY (2023)
Outcomes in Patients with FLT3-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy
Alexander E. Perl et al.
TRANSPLANTATION AND CELLULAR THERAPY (2023)
Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors
Yazan Numan et al.
AMERICAN JOURNAL OF HEMATOLOGY (2022)
Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial
Alexander E. Perl et al.
BLOOD (2022)
Molecular profile of FLT3-mutated relapsed/refractory AML patients in the phase 3 ADMIRAL study of gilteritinib
Catherine C. Smith et al.
Blood Advances (2022)
The Irreversible FLT3 Inhibitor FF-10101 Is Active Against a Diversity of FLT3 Inhibitor Resistance Mechanisms
Timothy T. Ferng et al.
MOLECULAR CANCER THERAPEUTICS (2022)
Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib
Alexander E. Perl et al.
BLOOD CANCER JOURNAL (2022)
Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysis
Shai Shimony et al.
ANNALS OF HEMATOLOGY (2022)
Phase 3 Trial of Gilteritinib Plus Azacitidine Vs Azacitidine for Newly Diagnosed FLT3mut+ AML Ineligible for Intensive Chemotherapy
Eunice S. Wang et al.
BLOOD (2022)
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
Hartmut Doehner et al.
BLOOD (2022)
Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia
Naval Daver et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
P-glycoprotein: new insights into structure, physiological function, regulation and alterations in disease
Iman Imtiyaz Ahmed Juvale et al.
HELIYON (2022)
AML-256 A Phase 1 Study of Gilteritinib in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia: Final Study Results
Keith W. Pratz et al.
Clinical Lymphoma Myeloma & Leukemia (2022)
Identification of Predictive Factors for Overall Survival and Response during Hypomethylating Treatment in Very Elderly (≥75 Years) Acute Myeloid Leukemia Patients: A Multicenter Real-Life Experience
Matteo Molica et al.
CANCERS (2022)
Updated Results from a Phase I/II Study of the Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia
Nicholas Short et al.
BLOOD (2022)
Gilteritinib Maintenance Therapy Post-Allogenic Stem-Cell Transplantation Improves the Prognosis of Patients with FLT3-Mutated AML
Toshiki Terao et al.
BLOOD (2022)
Efficacy and Safety of Gilteritinib Vs. Sorafenib As Post-Transplant Maintenance in Patients with FLT3-ITD Acute Myeloid Leukemia
Jason Yeh et al.
BLOOD (2022)
Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia
Richard T. Maziarz et al.
BONE MARROW TRANSPLANTATION (2021)
Gilteritinib for Relapsed Acute Myeloid Leukaemia with FLT3 Mutation during the COVID-19 Pandemic: Real World Experience from the UK National Health Service
Jad Othman et al.
BLOOD (2021)
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
Michael Heuser et al.
BLOOD (2021)
A new pre-emptive TKIs strategy for preventing relapse based on BCR/ABL monitoring for Ph plus ALL undergoing allo-HCT: a prospective clinical cohort study
Hui Liu et al.
LEUKEMIA (2021)
Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia
Amir T. Fathi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Single-cell DNA sequencing reveals complex mechanisms of resistance to quizartinib
Cheryl A. C. Peretz et al.
BLOOD ADVANCES (2021)
A Relapsing Meningeal Acute Myeloid Leukaemia FLT3-ITD+ Responding to Gilteritinib
Salvatore Perrone et al.
CHEMOTHERAPY (2021)
Phase 1 first-in-human study of irreversible FLT3 inhibitor FF-10101-01 in relapsed or refractory acute myeloid leukemia.
Mark J. Levis et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Triazole antifungal use for prophylaxis and treatment of invasive fungal diseases for patients receiving gilteritinib
Muneerah M. Aleissa et al.
LEUKEMIA RESEARCH (2021)
Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation-A Systematic Review and Meta-Analysis
Jan Philipp Bewersdorf et al.
TRANSPLANTATION AND CELLULAR THERAPY (2021)
Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 Inhibitors
Ahmad S. Alotaibi et al.
BLOOD CANCER DISCOVERY (2021)
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial
Andrew H. Wei et al.
BLOOD (2020)
Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor
Angela Joubert James et al.
CLINICAL PHARMACOKINETICS (2020)
An Iridociliochoroidal Myeloid Sarcoma Associated With Relapsed Acute Myeloid Leukemia With FLT3-ITD Mutation, Treated With Gilteritinib, an FLT3 Inhibitor
Ryan S. Kim et al.
JAMA OPHTHALMOLOGY (2020)
Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN)
Andreas Burchert et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia
Lindsey T. Brinton et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Gilteritinib: potent targeting of FLT3 mutations in AML
Mark Levis et al.
BLOOD ADVANCES (2020)
Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia
Christine M. McMahon et al.
CANCER DISCOVERY (2019)
Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial
Catherine C. Smith et al.
BLOOD (2019)
Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia
Nicholas J. Short et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2019)
Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia
Christine M. McMahon et al.
BLOOD ADVANCES (2019)
Clonal heterogeneity of FLT3-ITD detected by high-throughput amplicon sequencing correlates with adverse prognosis in acute myeloid leukemia
Katrin Schranz et al.
Oncotarget (2018)
Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: An open-label phase 1 study
Kensuke Usuki et al.
CANCER SCIENCE (2018)
A phase 3, trial of gilteritinib, as maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with FLT3-ITD+ AML.
Mark J. Levis et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations
Takeshi Yamaura et al.
BLOOD (2018)
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort
Maximilian Stahl et al.
BLOOD ADVANCES (2018)
A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations
Mark J. Levis et al.
BLOOD ADVANCES (2018)
Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia
Masamichi Mori et al.
INVESTIGATIONAL NEW DRUGS (2017)
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study
Alexander E. Perl et al.
LANCET ONCOLOGY (2017)
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
R. M. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
Marina Konopleva et al.
CANCER DISCOVERY (2016)
International Randomized Phase III Study of Elacytarabine Versus Investigator Choice in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Gail J. Roboz et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Stromal Niche Cells Protect Early Leukemic FLT3-ITD+ Progenitor Cells against First-Generation FLT3 Tyrosine Kinase Inhibitors
Amanda Parmar et al.
CANCER RESEARCH (2011)
The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia
Rosemary E. Gale et al.
BLOOD (2008)
Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis
M Yanada et al.
LEUKEMIA (2005)
Evolution of FLT3-ITD and D835 activating point mutations in relapsing acute myeloid leukemia and response to salvage therapy
J Tiesmeier et al.
LEUKEMIA RESEARCH (2004)
Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia:: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse
LY Shih et al.
BLOOD (2002)